October 5, 2026

IMVARIA Labs Adopts InVision Precision Cardiac Amyloid

InVision Medical Technology, an AI echocardiography company, and IMVARIA, a health tech diagnostic company, announced today that IMVARIA’s AI Lab will offer Precision Cardiac Amyloid (PCA), InVision’s FDA-cleared AI for the detection of cardiac amyloidosis from an echocardiogram.

January 7, 2026

Labcorp

Labcorp is a global leader of innovative and comprehensive laboratory services. The company’s Venture Fund invests in and supports early stage, private companies that are focused on improving health outcomes through innovative offerings aimed at making healthcare more convenient, accessible, data-driven and personalized.

November 18, 2025

Viz AI Partnership

Viz.ai, the leader in AI-powered disease detection and care coordination, today announced a strategic partnership with IMVARIA Inc., a health tech company pioneering AI-driven digital biomarker solutions. This collaboration expands Viz.ai’s pulmonary portfolio and introduces new AI capabilities that can assess for interstitial lung findings compatible with interstitial lung disease (ILD).

October 20, 2025

Virtual Bronch

The IMVARIA team conducted the pivotal VIRTUAL-BRONCH study of its new Bronchosolve solution to obtain data that underscores efficacy. In this study focused on better non-invasive diagnosis of lung cancer in cases of suspicious pulmonary nodules, topline results showed increased correct cancer classification independently and in combination with expert radiologists and pulmonologists.

September 3, 2025

NIH Sbir

IMVARIA was selected for this NIH SBIR grant because of our innovative technology, two prior FDA authorizations, growing commercial traction, a strong interdisciplinary team, and a unique go-to-market strategy. Together, these factors demonstrate scientific credibility and a clear path to enhancing patient care,” said Joshua Reicher, MD, Co-founder and CEO of IMVARIA. “Our Fibresolve AI adjunctive diagnostic service is already making a real difference in patients’ lives, giving us the confidence to apply it to other challenging problems, including oncology assessment.

June 10, 2025

Medical Horizons

The introduction of IMVARIA to the MENA region will give pulmonologists a powerful adjunct tool to help with verifying a diagnosis or ruling out ILD or IPF in a non-invasive manner,” said Guido Osti, CEO at Medical Horizons. “IMVARIA’s AI innovation complements the clinical decision-making that pulmonologists engage in every day. It adds another tool in the pulmonologist’s toolbox, making AI work for them.

May 18, 2025

Imvaria ATS25

IMVARIA’s Fibresolve received FDA authorization in early 2024 and has gone through a rigorous process to make it useful and reliable for pulmonologists. Fibresolve is available through IMVARIA’s centralized service that uses AI to help guide safe, non-invasive diagnoses. Fibresolve also has the distinction as the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association (AMA) in any disease.

January 13, 2025

Imvaria Screendx FDA

With the FDA 510(k) clearance of our ScreenDx digital solution, IMVARIA continues on the quest to make AI highly practical, useful, and easy to incorporate into medical practice for the thousands of pulmonologists who treat patients with lung diseases,” said Michael Muelly, MD, Co-founder and CTO of IMVARIA. “Our ultimate goal is to help patients with serious diseases, like ILD, get identified and placed into the diagnostic pathway as efficiently as possible, regardless of whether they were first seen in emergency, lung cancer screening, or specialty clinical settings. As medical doctors ourselves leading IMVARIA, we are putting another powerful tool into the hands of clinicians to help enhance decision-making.

January 16, 2024

Imvaria Fibresolve FDA

The FDA authorization of IMVARIA’s lead product Fibresolve, as a billable digital diagnostic tool for clinicians to use for patients, will expedite the medical community’s access to a non-invasive diagnostic solution using digital biomarkers in a novel way for lung fibrosis. This new authorization builds on the past medical and scientific assessments that the FDA had previously completed in assigning Fibresolve Breakthrough Device Designation.

November 1, 2023

IMVARIA Enters into Know-how Agreement with Mayo Clinic to Improve the Understanding of Cancer through AI Digital Biomarkers

AI biomarkers hold immense promise to unlock a more intricate understanding of many diseases, including cancers, and to advance healthcare with AI-powered precision

May 18, 2023

IMVARIA Announces Data Demonstrating Company’s Non-Invasive Digital Biomarker for Predicting Mortality in Interstitial Lung Diseases

Some patients with ILD may remain clinically stable for two years following diagnosis, while others will rapidly decline within six months. With a tool like Fibresolve that can independently and robustly predict outcomes, like mortality, physicians may better guide patients, including referral to clinical trials or more aggressive treatments, like lung transplants

August 16, 2022

Aiming Precision Medicine at Chronic Diseases

So far, biopharmaceutical companies post a poor track record in developing new treatments for chronic diseases. In thinking about the number of interventional clinical studies and the drug approvals for chronic diseases, Platt says: “There isn’t really a brilliant return on investment, which suggests we’re doing something wrong.”

IMVARIA Announces Presentations at American Thoracic Society International Conference Featuring IMVARIA’s AI-Driven Digital Biomarker Technology

Our vision at IMVARIA is to transform clinical decision-making into data science that can help physicians more accurately and rapidly diagnose patients, and therefore, potentially reduce the need for invasive biopsy testing,” said Joshua Reicher, MD, CEO of IMVARIA, and Michael Muelly, MD, CTO of IMVARIA.